Avizakimab, formerly known as BOS161721, represents a novel medicinal approach to treating immune-mediated disorders. This antibody medication selectively targets interleukin-18 , a vital cytokine https://aronihsa934260.pointblog.net/avizakimab-a-thorough-investigation-into-bos161721-s-promise-93226045